Prescribed exercise regimen versus usual care and hypochlorous acid wound solution versus placebo for treating venous leg ulcers: study protocol for a randomised controlled trial (Factorial4VLU)

JULL, Andrew, WADHAM, Angela, BULLEN, Chris, PARAG, Varsha, PARSONS, John GM, LAKING, George, WATERS, Jill, KLONIZAKIS, Markos and O'BRIEN, Jane (2021). Prescribed exercise regimen versus usual care and hypochlorous acid wound solution versus placebo for treating venous leg ulcers: study protocol for a randomised controlled trial (Factorial4VLU). BMJ Open, 11 (2), e043420-e043420.

[img]
Preview
PDF
Klonizakis-PrescribedExerciseRegimen(VoR).pdf - Published Version
Creative Commons Attribution Non-commercial.

Download (963kB) | Preview
Open Access URL: https://bmjopen.bmj.com/content/11/2/e043420 (Published version)
Link to published version:: https://doi.org/10.1136/bmjopen-2020-043420
Related URLs:

    Abstract

    <jats:sec><jats:title>Introduction</jats:title><jats:p>Compression is the mainstay of treatment for venous leg ulcers (VLUs) and there are few effective adjuvant treatments. There is only observational evidence supporting the use of hypochlorous acid (HOCl) as a topical wound solution on VLU and some limited randomised evidence for the effect of a prescribed regimen of exercise.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>The Factorial4VLU trial is a pragmatic, blinded, factorial randomised controlled trial, with 380 participants receiving either a prescribed exercise regimen compared with usual care and either active HOCl wound solution or placebo wound solution at each dressing change for up to 24 weeks. All participants will receive compression therapy. The primary outcome is the proportion of participants with healed VLU at 12 weeks after randomisation as adjudicated by blinded review of ulcer photographs. Secondary outcomes are proportion healed at 24 weeks, time to healing, estimated change in ulcer area, change in 2-Minute Walk Test, change in health-related quality of life, incidence of infection and incidence of all-cause adverse events. If either of the interventions shows a statistically significant positive difference on healing outcomes, cost-effectiveness will be modelled using a health service perspective.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>The Factorial4VLU trial received ethical approval from the Northern B Health and Disability Ethics Committee. We plan to publish the results within 1 year of trial completion and will include the results on the trial registration page.</jats:p></jats:sec><jats:sec><jats:title>Trial registration numbers</jats:title><jats:p>Australia and New Zealand Clinical Trials Register (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.anzctr.org.au">http://www.anzctr.org.au</jats:ext-link>) (ACTRN12620000116921); Universal Trial Number (WHO) (U1111-1236-2997).</jats:p></jats:sec>

    Item Type: Article
    Uncontrolled Keywords: 1103 Clinical Sciences; 1117 Public Health and Health Services; 1199 Other Medical and Health Sciences
    Identification Number: https://doi.org/10.1136/bmjopen-2020-043420
    Page Range: e043420-e043420
    SWORD Depositor: Symplectic Elements
    Depositing User: Symplectic Elements
    Date Deposited: 23 Feb 2021 17:21
    Last Modified: 17 Mar 2021 14:45
    URI: http://shura.shu.ac.uk/id/eprint/28197

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year

    View more statistics